Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Ongoing EBV DNA-integral randomized phase II/III trial (NRG-HN001): post-chemoradiation plasma EBV DNA is used to assign adjuvant therapy. Enrollment 924. A peer-reviewed primary efficacy results paper was not identified as of 13 Nov 2026.

NRG Oncology